Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 8/20 | 0.39 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225625 | 1.00 | PYGL (0.39) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL21235192 | 1.00 | PYGL (0.39) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL25532234 | 0.91 | PYGL (0.38) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL25531407 | 0.90 | PYGL (0.38) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL25531409 | 0.90 | PYGL (0.38) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL25532231 | 0.90 | PYGL (0.38) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL21225298 | 0.86 | PYGL (0.39) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL21225563 | 0.86 | PYGL (0.39) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL21225314 | 0.86 | PYGL (0.39) | PYGLPYGMHRH4EHMT2DRD4 | |
| SCHEMBL21225322 | 0.86 | PYGL (0.39) | PYGLPYGMHRH4EHMT2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | claimed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | claimed |
| EP-3746430-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | Padforward LLC (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | claimed |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADI2, PADI1, PADI4 | PYGL 113/4885PYGM 201/4885HRH4 2377/4885 |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | PYGL 110/4885PYGM 222/4885HRH4 2617/4885 |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADI2, PADI1, PADI4 | PYGL 113/4885PYGM 201/4885HRH4 2377/4885 |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | PYGL 121/4885PYGM 263/4885HRH4 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.